Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Meir Bialer

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Living Beings

Disorders

Epilepsy

Concepts & Ideas

Procedures

Physiology

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
49
Yagen, Boris
16
Levy, René
16
Perucca, Emilio
12
Isoherranen, Nina
11
Doose, Dennis
11
Finnell, Richard
10
Sobol, Eyal
10
Spiegelstein, Ofer
10
White, Steve
8
Blotnik, Simcha
8
Sintov, Amnon
8
Johannessen, Svein
7
Kupferberg, Harvey
7
Samara, Emil
7
Soback, Stefan

Sign-in to see all Coauthors

Publications

TOP 3
Okada Akinobu; Noyori Hiroko; Yagen Boris; Shimshoni Jakob Avi; Bialer Meir; Fujiwara Michio
Anticonvulsant profile and teratogenic evaluation of potent new analogues of a valproic acid urea derivative in NMRI mice.
Zannikos Peter; Novak Gerald; Yao Caiping; Verhaeghe Tom; Franc Monique A; Solanki Bhavna; Bialer Meir
Pharmacokinetics of carisbamate (RWJ-333369) in healthy Japanese and Western subjects.
Pessah Neta; Bialer Meir; Wlodarczyk Bogdan; Finnell Richard H; Yagen Boris
Alpha-fluoro-2,2,3,3-tetramethylcyclopropanecarboxamide, a novel potent anticonvulsant derivative of a cyclic analogue of valproic acid.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Meir Bialer (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Okada Akinobu; Noyori Hiroko; Yagen Boris; Shimshoni Jakob Avi; Bialer Meir; Fujiwara Michio
Anticonvulsant profile and teratogenic evaluation of potent new analogues of a valproic acid urea derivative in NMRI mice.
Birth defects research. Part B, Developmental and reproductive toxicology 2009;86(5):394-401.
2009: Zannikos Peter; Novak Gerald; Yao Caiping; Verhaeghe Tom; Franc Monique A; Solanki Bhavna; Bialer Meir
Pharmacokinetics of carisbamate (RWJ-333369) in healthy Japanese and Western subjects.
Epilepsia 2009;50(8):1850-9.
2009: Pessah Neta; Bialer Meir; Wlodarczyk Bogdan; Finnell Richard H; Yagen Boris
Alpha-fluoro-2,2,3,3-tetramethylcyclopropanecarboxamide, a novel potent anticonvulsant derivative of a cyclic analogue of valproic acid.
Journal of medicinal chemistry 2009;52(8):2233-42.
2009: Shimshoni Jakob A; Dalton Emma C; Watson Peter; Boris Yagen; Bialer Meir; Harwood Adrian J
Evaluation of the effects of propylisopropylacetic acid (PIA) on neuronal growth cone morphology.
Neuropharmacology 2009;56(4):831-7.
2009: Bialer Meir; Johannessen Svein I; Levy René H; Perucca Emilio; Tomson Torbjörn; White H Steve
Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX).
Epilepsy research 2009;83(1):1-43.
2008: Okada Akinobu; Onishi Yuko; Yagen Boris; Shimshoni Jakob Avi; Kaufmann Dan; Bialer Meir; Fujiwara Michio
Tetramethylcyclopropyl analogue of the leading antiepileptic drug, valproic acid: evaluation of the teratogenic effects of its amide derivatives in NMRI mice.
Birth defects research. Part A, Clinical and molecular teratology 2008;82(9):610-21.
2008: Shimshoni Jakob Avi; Yagen Boris; Pessah Neta; Wlodarczyk Bogdan; Finnell Richard H; Bialer Meir
Anticonvulsant profile and teratogenicity of 3,3-dimethylbutanoylurea: a potential for a second generation drug to valproic acid.
Epilepsia 2008;49(7):1202-12.
2008: Shimshoni Jakob Avi; Bialer Meir; Yagen Boris
Synthesis and anticonvulsant activity of aromatic tetramethylcyclopropanecarboxamide derivatives.
Bioorganic & medicinal chemistry 2008;16(11):6297-305.
2008: Kaufmann Dan; Yagen Boris; Minert Anne; Tal Michael; Devor Marshall; Bialer Meir
Evaluation of the enantioselective antiallodynic and pharmacokinetic profile of propylisopropylacetamide, a chiral isomer of valproic acid amide.
Neuropharmacology 2008;54(4):699-707.
2007: Shimshoni Jakob Avi; Bialer Meir; Wlodarczyk Bogdan; Finnell Richard H; Yagen Boris
Potent anticonvulsant urea derivatives of constitutional isomers of valproic acid.
Journal of medicinal chemistry 2007;50(25):6419-27.
2007: Bialer Meir
Generic products of antiepileptic drugs (AEDs): is it an issue?
Epilepsia 2007;48(10):1825-32.
2007: Perucca Emilio; French Jacqueline; Bialer Meir
Development of new antiepileptic drugs: challenges, incentives, and recent advances.
Lancet neurology 2007;6(9):793-804.
2007: Chien Shuchean; Yao Caiping; Mertens Annemie; Verhaeghe Tom; Solanki Bhavna; Doose Dennis R; Novak Gerald; Bialer Meir
An interaction study between the new antiepileptic and CNS drug carisbamate (RWJ-333369) and lamotrigine and valproic acid.
Epilepsia 2007;48(7):1328-38.
2007: Mannens G S J; Hendrickx J; Janssen C G M; Chien S; Van Hoof B; Verhaeghe T; Kao M; Kelley M F; Goris I; Bockx M; Verreet B; Bialer M; Meuldermans W
The absorption, metabolism, and excretion of the novel neuromodulator RWJ-333369 (1,2-ethanediol, [1-2-chlorophenyl]-, 2-carbamate, [S]-) in humans.
Drug metabolism and disposition: the biological fate of chemicals 2007;35(4):554-65.
2007: Elger Christian; Bialer Meir; Cramer Joyce A; Maia Joana; Almeida Luis; Soares-da-Silva Patrício
Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures.
Epilepsia 2007;48(3):497-504.
2007: Shimshoni J A; Dalton E C; Jenkins A; Eyal S; Ewan K; Williams R S B; Pessah N; Yagen B; Harwood A J; Bialer M
The effects of central nervous system-active valproic acid constitutional isomers, cyclopropyl analogs, and amide derivatives on neuronal growth cone behavior.
Molecular pharmacology 2007;71(3):884-92.
2007: Bialer Meir; Yagen Boris
Valproic Acid: second generation.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2007;4(1):130-7.
2007: Bialer Meir; Johannessen Svein I; Kupferberg Harvey J; Levy René H; Perucca Emilio; Tomson Torbjörn
Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII).
Epilepsy research 2007;73(1):1-52.
2007: Sobol Eyal; Yagen Boris; Lamb John G; White H Steve; Wlodarczyk Bogdan J; Finnell Richard H; Bialer Meir
Anticonvulsant activity, neural tube defect induction, mutagenicity and pharmacokinetics of a new potent antiepileptic drug, N-methoxy-2,2,3,3-tetramethylcyclopropane carboxamide.
Epilepsy research 2007;73(1):75-84.
2007: Bialer Meir
Clinical pharmacology of parenteral use of antiepileptic drugs.
Epilepsia 2007;48 Suppl 8():46-8.
2007: Bialer Meir
Extended-release formulations for the treatment of epilepsy.
CNS drugs 2007;21(9):765-74.
2006: Chien Suchean; Bialer Meir; Solanki Bhavna; Verhaeghe Tom; Doose Dennis R; Novak Gerald; Yao Caiping
Pharmacokinetic interaction study between the new antiepileptic and CNS drug RWJ-333369 and carbamazepine in healthy adults.
Epilepsia 2006;47(11):1830-40.
2006: Yao Caiping; Doose Dennis R; Novak Gerald; Bialer Meir
Pharmacokinetics of the new antiepileptic and CNS drug RWJ-333369 following single and multiple dosing to humans.
Epilepsia 2006;47(11):1822-9.
2006: Eyal S; Lamb J G; Smith-Yockman M; Yagen B; Fibach E; Altschuler Y; White H S; Bialer M
The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver.
British journal of pharmacology 2006;149(3):250-60.
2006: Sobol Eyal; Yagen Boris; Steve White H; Wilcox Karen S; Lamb John G; Pappo Orit; Wlodarczyk Bogdan J; Finnell Richard H; Bialer Meir
Preclinical evaluation of 2,2,3,3-tetramethylcyclopropanecarbonyl-urea, a novel, second generation to valproic acid, antiepileptic drug.
Neuropharmacology 2006;51(4):933-46.
2006: Okada Akinobu; Onishi Yuko; Aoki Yoshinobu; Yagen Boris; Sobol Eyal; Bialer Meir; Fujiwara Michio
Teratology study of derivatives of tetramethylcyclopropyl amide analogues of valproic acid in mice.
Birth defects research. Part B, Developmental and reproductive toxicology 2006;77(3):227-33.
2006: Bialer Meir
New antiepileptic drugs that are second generation to existing antiepileptic drugs.
Expert opinion on investigational drugs 2006;15(6):637-47.
2005: Bialer Meir
The pharmacokinetics and interactions of new antiepileptic drugs: an overview.
Therapeutic drug monitoring 2005;27(6):722-6.
2005: Winkler Ilan; Sobol Eyal; Yagen Boris; Steinman Amir; Devor Marshall; Bialer Meir
Efficacy of antiepileptic tetramethylcyclopropyl analogues of valproic acid amides in a rat model of neuropathic pain.
Neuropharmacology 2005;49(8):1110-20.
2005: Sobol Eyal; Yagen Boris; Winkler Ilan; Britzi Malka; Gibson Dan; Bialer Meir
Pharmacokinetics and metabolism of a new potent antiepileptic drug, 2,2,3,3-tetramethycyclopropanecarbonylurea, in rats.
Drug metabolism and disposition: the biological fate of chemicals 2005;33(10):1538-46.
2005: Winkler Ilan; Blotnik Simcha; Shimshoni Jakob; Yagen Boris; Devor Marshall; Bialer Meir
Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain.
British journal of pharmacology 2005;146(2):198-208.
2005: Mimrod Dorit; Specchio Luigi M; Britzi Malka; Perucca Emilio; Specchio Nicola; La Neve Angela; Soback Stefan; Levy René H; Gatti Giuliana; Doose Dennis R; Maryanoff Bruce E; Bialer Meir
A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy.
Epilepsia 2005;46(7):1046-54.
2005: Eyal Sara; Yagen Boris; Shimshoni Jakob; Bialer Meir
Histone deacetylases inhibition and tumor cells cytotoxicity by CNS-active VPA constitutional isomers and derivatives.
Biochemical pharmacology 2005;69(10):1501-8.
2005: Okada Akinobu; Kushima Kiyoshi; Aoki Yoshinobu; Bialer Meir; Fujiwara Michio
Identification of early-responsive genes correlated to valproic acid-induced neural tube defects in mice.
Birth defects research. Part A, Clinical and molecular teratology 2005;73(4):229-38.
2005: Britzi Malka; Perucca Emilio; Soback Stefan; Levy René H; Fattore Cinzia; Crema Francesca; Gatti Giuliana; Doose Dennis R; Maryanoff Bruce E; Bialer Meir
Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine.
Epilepsia 2005;46(3):378-84.
2005: Sobol Eyal; Bialer Meir
Critical analysis of the discrepancy between V(beta) and V(ss) for drugs exhibiting different two-compartment disposition profiles.
Biopharmaceutics & drug disposition 2005;26(2):51-8.
2005: Shank Richard P; Doose Dennis R; Streeter Anthony J; Bialer Meir
Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase.
Epilepsy research 2005;63(2-3):103-12.
2004: Bialer Meir; Twyman Roy E; White H Steve
Correlation analysis between anticonvulsant ED50 values of antiepileptic drugs in mice and rats and their therapeutic doses and plasma levels.
Epilepsy & behavior : E&B 2004;5(6):866-72.
2004: Shaltiel Galit; Shamir Alon; Shapiro Joseph; Ding Daobin; Dalton Emma; Bialer Meir; Harwood Adrian J; Belmaker Robert H; Greenberg Miriam L; Agam Galila
Valproate decreases inositol biosynthesis.
Biological psychiatry 2004;56(11):868-74.
2004: Okada Akinobu; Aoki Yoshinobu; Kushima Kiyoshi; Kurihara Hiroshi; Bialer Meir; Fujiwara Michio
Polycomb homologs are involved in teratogenicity of valproic acid in mice.
Birth defects research. Part A, Clinical and molecular teratology 2004;70(11):870-9.
2004: Bialer Meir; Johannessen Svein I; Kupferberg Harvey J; Levy René H; Perucca Emilio; Tomson Torbjörn
Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII).
Epilepsy research 2004;61(1-3):1-48.
2004: Sobol Eyal; Bialer Meir; Yagen Boris
Tetramethylcyclopropyl analogue of a leading antiepileptic drug, valproic acid. Synthesis and evaluation of anticonvulsant activity of its amide derivatives.
Journal of medicinal chemistry 2004;47(17):4316-26.
2004: Eyal Sara; Yagen Boris; Sobol Eyal; Altschuler Yoram; Shmuel Miriam; Bialer Meir
The activity of antiepileptic drugs as histone deacetylase inhibitors.
Epilepsia 2004;45(7):737-44.
2004: Sobol Eyal; Bialer Meir
The relationships between half-life (t1/2) and mean residence time (MRT) in the two-compartment open body model.
Biopharmaceutics & drug disposition 2004;25(4):157-62.
2004: Sobol Eyal; Bialer Meir
Mathematical comparison between volume of distribution (V) and volume of distribution at steady-state (Vss) utilizing model-independent approach.
Biopharmaceutics & drug disposition 2004;25(2):99-101.
2004: Okada Akinobu; Kurihara Hiroshi; Aoki Yoshinobu; Bialer Meir; Fujiwara Michio
Amidic modification of valproic acid reduces skeletal teratogenicity in mice.
Birth defects research. Part B, Developmental and reproductive toxicology 2004;71(1):47-53.
2004: Isoherranen Nina; Levy René H; Yagen Boris; Woodhead José H; White H Steve; Bialer Meir
Metabolism of a new antiepileptic drug, N-methyl-tetramethylcyclopropanecarboxamide, and anticonvulsant activity of its metabolites.
Epilepsy research 2004;58(1):1-12.
2004: Bialer Meir; Doose Dennis R; Murthy Bindu; Curtin Christopher; Wang Shean-Sheng; Twyman Roy E; Schwabe Stefan
Pharmacokinetic interactions of topiramate.
Clinical pharmacokinetics 2004;43(12):763-80.
2003: Isoherranen Nina; Spiegelstein Ofer; Bialer Meir; Zhang Jing; Merriweather Michelle; Yagen Boris; Roeder Michael; Triplett Aleata A; Schurig Volker; Finnell Richard H
Developmental outcome of levetiracetam, its major metabolite in humans, 2-pyrrolidinone N-butyric acid, and its enantiomer (R)-alpha-ethyl-oxo-pyrrolidine acetamide in a mouse model of teratogenicity.
Epilepsia 2003;44(10):1280-8.
2003: Isoherranen Nina; White H Steve; Klein Brian D; Roeder Michael; Woodhead José H; Schurig Volker; Yagen Boris; Bialer Meir
Pharmacokinetic-pharmacodynamic relationships of (2S,3S)-valnoctamide and its stereoisomer (2R,3S)-valnoctamide in rodent models of epilepsy.
Pharmaceutical research 2003;20(8):1293-301.
2003: Doose Dennis R; Brodie Martin J; Wilson Elaine A; Chadwick David; Oxbury John; Berry David J; Schwabe Stefan; Bialer Meir
Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients.
Epilepsia 2003;44(7):917-22.
2003: Isoherranen Nina; Yagen Boris; Spiegelstein Ofer; Finnell Richard H; Merriweather Michelle; Woodhead Jose H; Wlodarczyk Bogdan; White H Steve; Bialer Meir
Anticonvulsant activity, teratogenicity and pharmacokinetics of novel valproyltaurinamide derivatives in mice.
British journal of pharmacology 2003;139(4):755-64.
2003: Johannessen Svein I; Battino Dina; Berry David J; Bialer Meir; Krämer Günter; Tomson Torbjörn; Patsalos Philip N
Therapeutic drug monitoring of the newer antiepileptic drugs.
Therapeutic drug monitoring 2003;25(3):347-63.
2003: Britzi Malka; Soback Stefan; Isoherranen Nina; Levy Rene' H; Perucca Emilio; Doose Dennis R; Maryanoff Bruce E; Bialer Meir
Analysis of topiramate and its metabolites in plasma and urine of healthy subjects and patients with epilepsy by use of a novel liquid chromatography-mass spectrometry assay.
Therapeutic drug monitoring 2003;25(3):314-22.
2003: Isoherranen Nina; Yagen Boris; Spiegelstein Ofer; Steinman Amir; Finnell Richard H; Bialer Meir
Gas chromatographic determination of novel valproyl taurinamide derivatives in mouse and dog plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;788(1):125-36.
2003: Doose Dennis R; Wang Shean-Sheng; Padmanabhan Mukund; Schwabe Stefan; Jacobs David; Bialer Meir
Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects.
Epilepsia 2003;44(4):540-9.
2003: Isoherranen Nina; Yagen Boris; Bialer Meir
New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet?
Current opinion in neurology 2003;16(2):203-11.
2003: Isoherranen Nina; Yagen Boris; Woodhead José H; Spiegelstein Ofer; Blotnik Simcha; Wilcox Karen S; Finnell Richard H; Bennett Gregory D; White H Steve; Bialer Meir
Characterization of the anticonvulsant profile and enantioselective pharmacokinetics of the chiral valproylamide propylisopropyl acetamide in rodents.
British journal of pharmacology 2003;138(4):602-13.
2003: Williams John; Bialer Meir; Johannessen Svein I; Krämer Günther; Levy René; Mattson Richard H; Perucca Emilio; Patsalos Philip N; Wilson John F
Interlaboratory variability in the quantification of new generation antiepileptic drugs based on external quality assessment data.
Epilepsia 2003;44(1):40-5.
2002: Bialer M; Johannessen S I; Kupferberg H J; Levy R H; Loiseau P; Perucca E
Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI).
Epilepsy research 2002;51(1-2):31-71.
2002: Sachdeo R C; Sachdeo S K; Levy R H; Streeter A J; Bishop F E; Kunze K L; Mather G G; Roskos L K; Shen D D; Thummel K E; Trager W F; Curtin C R; Doose Dennis R; Gisclon L G; Bialer Meir
Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients.
Epilepsia 2002;43(7):691-6.
2002: Isoherranen Nina; White H Steve; Finnell Richard H; Yagen Boris; Woodhead José H; Bennett Gregory D; Wilcox Karen S; Barton Matthew E; Bialer Meir
Anticonvulsant profile and teratogenicity of N-methyl-tetramethylcyclopropyl carboxamide: a new antiepileptic drug.
Epilepsia 2002;43(2):115-26.
2002: Bialer Meir
New antiepileptic drugs currently in clinical trials: is there a strategy in their development?
Therapeutic drug monitoring 2002;24(1):85-90.
2002: Bialer Meir; Walker Matthew C; Sander Josemir W
Pros and cons for the development of new antiepileptic drugs.
CNS drugs 2002;16(5):285-9.
2001: Wasserman M; Yagen B; Blotnik S; Papo N; Bialer M
Stereoselective pharmacokinetic analysis and antiepileptic activity of N-2-hydroxypropyl valpromide, a central nervous system--active chiral valproylamide.
Therapeutic drug monitoring 2001;23(4):414-20.
2001: Isoherranen N; Woodhead J H; White H S; Bialer M
Anticonvulsant profile of valrocemide (TV1901): a new antiepileptic drug.
Epilepsia 2001;42(7):831-6.
2001: Isoherranen N; Yagen B; Soback S; Roeder M; Schurig V; Bialer M
Pharmacokinetics of levetiracetam and its enantiomer (R)-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs.
Epilepsia 2001;42(7):825-30.
2001: Bialer M; Johannessen S I; Kupferberg H J; Levy R H; Loiseau P; Perucca E
Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V).
Epilepsy research 2001;43(1):11-58.
2000: Spiegelstein O; Yagen B; Bennett G D; Finnell R H; Blotnik S; Bialer M
Stereoselective pharmacokinetic analysis of valnoctamide, a CNS-active chiral amide analogue of valproic acid, in dogs, rats, and mice.
Therapeutic drug monitoring 2000;22(5):574-81.
2000: Britzi M; Bialer M; Arcavi L; Shachbari A; Kapitulnik T; Soback S
Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping Israeli ethnic groups.
Therapeutic drug monitoring 2000;22(5):510-6.
2000: Volosov A; Yagen B; Bialer M
Comparative stereoselective pharmacokinetic analysis of 10-hydroxycarbazepine after oral administration of its individual enantiomers and the racemic mixture to dogs.
Epilepsia 2000;41(9):1107-11.
2000: Isoherranen N; Roeder M; Soback S; Yagen B; Schurig V; Bialer M
Enantioselective analysis of levetiracetam and its enantiomer R-alpha-ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion trap mass spectrometric detection.
Journal of chromatography. B, Biomedical sciences and applications 2000;745(2):325-32.
2000: Spiegelstein O; Kroetz D L; Levy R H; Yagen B; Hurst S I; Levi M; Haj-Yehia A; Bialer M
Structure activity relationship of human microsomal epoxide hydrolase inhibition by amide and acid analogues of valproic acid.
Pharmaceutical research 2000;17(2):216-21.
2000: Volosov A; Bialer M; Xiaodong S; Perucca E; Sintov A; Yagen B
Simultaneous stereoselective high-performance liquid chromatographic determination of 10-hydroxycarbazepine and its metabolite carbamazepine-10,11-trans-dihydrodiol in human urine.
Journal of chromatography. B, Biomedical sciences and applications 2000;738(2):419-25.
1999: Volosov A; Xiaodong S; Perucca E; Yagen B; Sintov A; Bialer M
Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects.
Clinical pharmacology and therapeutics 1999;66(6):547-53.
1999: Bialer M
Pharmacokinetic considerations in the design of better and safer new antiepileptic drugs.
Journal of controlled release : official journal of the Controlled Release Society 1999;62(1-2):187-92.
1999: Spiegelstein O; Yagen B; Levy R H; Finnell R H; Bennett G D; Roeder M; Schurig V; Bialer M
Stereoselective pharmacokinetics and pharmacodynamics of propylisopropyl acetamide, a CNS-active chiral amide analog of valproic acid.
Pharmaceutical research 1999;16(10):1582-8.
1999: Spiegelstein O; Yagen B; Bialer M
Structure-pharmacokinetic-pharmacodynamic relationships of N-alkyl derivatives of the new antiepileptic drug valproyl glycinamide.
Epilepsia 1999;40(5):545-52.
1999: Volosov A; Sintov A; Bialer M
Stereoselective pharmacokinetic analysis of the antiepileptic 10-hydroxycarbazepine in dogs.
Therapeutic drug monitoring 1999;21(2):219-23.
1999: Sussan S; Dagan A; Blotnik S; Bialer M
The structural requirements for the design of antiepileptic-glycine derivatives.
Epilepsy research 1999;34(2-3):207-20.
1999: Bialer M; Johannessen S I; Kupferberg H J; Levy R H; Loiseau P; Perucca E
Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV).
Epilepsy research 1999;34(1):1-41.
1999: Volosov A; Bialer M
Use of mean residence time to determine the magnitude of difference between rate constants and to calculate tmax in the Bateman equation.
Biopharmaceutics & drug disposition 1999;20(1):3-9.
1999: Sussan S; Dagan A; Bialer M
Pharmacokinetic analysis and anticonvulsant activity of glycine and glycinamide derivatives.
Epilepsy research 1999;33(1):11-21.
1999: Spiegelstein O; Bialer M; Radatz M; Nau H; Yagen B
Enantioselective synthesis and teratogenicity of propylisopropyl acetamide, a CNS-active chiral amide analogue of valproic acid.
Chirality 1999;11(8):645-50.
1998: Bialer M; Arcavi L; Sussan S; Volosov A; Yacobi A; Moros D; Levitt B; Laor A
Existing and new criteria for bioequivalence evaluation of new controlled release (CR) products of carbamazepine.
Epilepsy research 1998;32(3):371-8.
1998: Bialer M; Yacobi A; Moros D; Levitt B; Houle J M; Munsaka M S
Criteria to assess in vivo performance and bioequivalence of generic controlled-release formulations of carbamazepine.
Epilepsia 1998;39(5):513-9.
1998: Blotnik S; Bergman F; Bialer M
Disposition of two tetramethylcyclopropane analogues of valpromide in the brain, liver, plasma and urine of rats.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 1998;6(2):93-8.
1998: Bialer M; Levy R H; Perucca E
Does carbamazepine have a narrow therapeutic plasma concentration range?
Therapeutic drug monitoring 1998;20(1):56-9.
1997: Hadad S; Bialer M
Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide.
Biopharmaceutics & drug disposition 1997;18(7):557-66.
1997: Spiegelstein O; Bialer M; Yagen B
Isolation of N,N-dialkylated derivatives of valproylglycinamide from dog plasma by active charcoal adsorption and their quantification by high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 1997;698(1-2):195-200.
1997: Blotnik S; Bergman F; Bialer M
The disposition of valproyl glycinamide and valproyl glycine in rats.
Pharmaceutical research 1997;14(7):873-8.
1997: Levi M; Yagen B; Bialer M
Pharmacokinetics and antiepileptic activity of valproyl hydroxamic acid derivatives.
Pharmaceutical research 1997;14(2):213-7.
1996: Bialer M; Johannessen S I; Kupferberg H J; Levy R H; Loiseau P; Perucca E
Progress report on new antiepileptic drugs: a summary of the Third Eilat Conference.
Epilepsy research 1996;25(3):299-319.
1996: Bialer M; Kadry B; Abdul-Hai A; Haj-Yehia A; Sterling J; Herzig Y; Shirvan M
Pharmacokinetic and pharmacodynamic analysis of (E)-2-ene valproyl derivatives of glycine and valproyl derivatives of nipecotic acid.
Biopharmaceutics & drug disposition 1996;17(7):565-75.
1996: Perucca E; Bialer M
The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine.
Clinical pharmacokinetics 1996;31(1):29-46.
1996: Blotnik S; Bergman F; Bialer M
Disposition of valpromide, valproic acid, and valnoctamide in the brain, liver, plasma, and urine of rats.
Drug metabolism and disposition: the biological fate of chemicals 1996;24(5):560-4.
1996: Bialer M; Hadad S; Kadry B; Abdul-Hai A; Haj-Yehia A; Sterling J; Herzig Y; Yagen B
Pharmacokinetic analysis and antiepileptic activity of tetra-methylcyclopropane analogues of valpromide.
Pharmaceutical research 1996;13(2):284-9.
1995: Stables J P; Bialer M; Johannessen S I; Kupferberg H J; Levy R H; Loiseau P; Perucca E
Progress report on new antiepileptic drugs. A summary of the Second Eilat Conference.
Epilepsy research 1995;22(3):235-46.
1995: Bialer M; Sussan S; Abu Salach O; Danenberg H D; Ben-David J; Gibor Y; Laor A
Criteria to assess in vivo performance of sustained release products: application to diltiazem formulations.
Journal of pharmaceutical sciences 1995;84(10):1160-3.
1995: Hadad S; Bialer M
Pharmacokinetic analysis and antiepileptic activity of N-valproyl derivatives of GABA and glycine.
Pharmaceutical research 1995;12(6):905-10.
1995: Samara E; Avnir D; Ladkani D; Bialer M
Pharmacokinetic analysis of diethylcarbonate prodrugs of ibuprofen and naproxen.
Biopharmaceutics & drug disposition 1995;16(3):201-10.
1994: Perucca E; Gatti G; Cipolla G; Spina E; Barel S; Soback S; Gips M; Bialer M
Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers.
Clinical pharmacology and therapeutics 1994;56(5):471-6.
1994: abu Salach O; Hadad S; Haj-Yehia A; Sussan S; Bialer M
Comparative pharmacokinetic and pharmacodynamic analysis of phthaloyl glycine derivatives with potential antiepileptic activity.
Pharmaceutical research 1994;11(10):1429-34.
1994: Barel S; Yagen B; Bialer M
Pharmacokinetic profile of conjugated verrucarol urinary metabolites in dogs.
Biopharmaceutics & drug disposition 1994;15(7):609-16.
1994: Bialer M; Haj-Yehia A; Badir K; Hadad S
Can we develop improved derivatives of valproic acid?
Pharmacy world & science : PWS 1994;16(1):2-6.
1994: Bialer M; Hadad S; Golomb G; Barel S; Samara E; Abu Salach O; Berkman N; Danenberg H D; Ben David J; Caron D
Pharmacokinetic analysis of two new sustained-release products of diltiazem designed for twice- and once-daily treatment.
Biopharmaceutics & drug disposition 1994;15(1):45-52.
1993: Bialer M
Comparative pharmacokinetics of the newer antiepileptic drugs.
Clinical pharmacokinetics 1993;24(6):441-52.
1993: Hadad S; Vree T B; van der Kleijn E; Bialer M
Pharmacokinetic analysis and anticonvulsant activity of two polyesteric prodrugs of valproic acid.
Biopharmaceutics & drug disposition 1993;14(1):51-9.
1993: Yagen B; Bialer M
Metabolism and pharmacokinetics of T-2 toxin and related trichothecenes.
Drug metabolism reviews 1993;25(3):281-323.
1992: Hadad S; Vree T B; van der Kleijn E; Bialer M
Pharmacokinetic analysis of ester prodrugs of valproic acid.
Journal of pharmaceutical sciences 1992;81(10):1047-50.
1992: Haj-Yehia A; Hadad S; Bialer M
Pharmacokinetic analysis of the structural requirements for forming "stable" analogues of valpromide.
Pharmaceutical research 1992;9(8):1058-63.
1992: Bialer M
Pharmacokinetic evaluation of sustained release formulations of antiepileptic drugs. Clinical implications.
Clinical pharmacokinetics 1992;22(1):11-21.
1991: Badir K; Haj-Yehia A; Vree T B; van der Kleijn E; Bialer M
Pharmacokinetics and anticonvulsant activity of three monoesteric prodrugs of valproic acid.
Pharmaceutical research 1991;8(6):750-3.
1991: Bialer M
Clinical pharmacology of valpromide.
Clinical pharmacokinetics 1991;20(2):114-22.
1990: Samara E; Bialer M; Harvey D J
Pharmacokinetics of urinary metabolites of cannabidiol in the dog.
Biopharmaceutics & drug disposition 1990;11(9):785-95.
1990: Haj-Yehia A; Bialer M
Structure-pharmacokinetic relationships in a series of short fatty acid amides that possess anticonvulsant activity.
Journal of pharmaceutical sciences 1990;79(8):719-24.
1990: Barel S; Yagen B; Bialer M
Pharmacokinetics of the trichothecene mycotoxin verrucarol in dogs.
Journal of pharmaceutical sciences 1990;79(6):548-51.
1990: Samara E; Bialer M; Bar-On H; Harvey D J
Identification of metabolites of the 1",1"-dimethylheptyl analogue of cannabidiol in rat and dog in vivo.
Xenobiotica; the fate of foreign compounds in biological systems 1990;20(5):447-55.
1990: Billig H; Ziv E; Bar-On H; Bialer M
The disposition of valpromide in rats and the isolated perfused rat liver.
Drug metabolism and disposition: the biological fate of chemicals 1990;18(2):238-44.
1990: Samara E; Bialer M; Harvey D J
Identification of glucose conjugates as major urinary metabolites of cannabidiol in the dog.
Xenobiotica; the fate of foreign compounds in biological systems 1990;20(2):177-83.
1990: Bialer M; Haj-Yehia A; Barzaghi N; Pisani F; Perucca E
Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects.
European journal of clinical pharmacology 1990;38(3):289-91.
1989: Haj-Yehia A; Bialer M
Structure-pharmacokinetic relationships in a series of valpromide derivatives with antiepileptic activity.
Pharmaceutical research 1989;6(8):683-9.
1988: Samara E; Bialer M
Pharmacokinetics of the dimethylheptyl homolog of cannabidiol in dogs.
Drug metabolism and disposition: the biological fate of chemicals 1988;16(6):875-9.
1988: Haj-Yehia A; Bialer M
Pharmacokinetics of a valpromide isomer, valnoctamide, in dogs.
Journal of pharmaceutical sciences 1988;77(10):831-4.
1988: Bialer M; Wu W H; Faulkner R D; Silber B M; Yacobi A
In vitro protein binding interaction studies involving cefixime.
Biopharmaceutics & drug disposition 1988;9(3):315-20.
1988: Samara E; Bialer M; Mechoulam R
Pharmacokinetics of cannabidiol in dogs.
Drug metabolism and disposition: the biological fate of chemicals 1988;16(3):469-72.
1988: Sintov A; Bialer M; Yagen B
Pharmacokinetics and protein binding of trichothecene mycotoxins, T-2 toxin and HT-2 toxin, in dogs.
Toxicon : official journal of the International Society on Toxinology 1988;26(2):153-60.
1987: Hussein Z; Bialer M; Friedman M; Raz I
Pharmacokinetic analysis of sustained-release dosage forms of theophylline in humans: comparison of single and multiple dose studies.
Biopharmaceutics & drug disposition 1987;8(5):427-35.
1987: Sintov A; Bialer M; Yagen B
Pharmacokinetics of T-2 tetraol, a urinary metabolite of the trichothecene mycotoxin, T-2 toxin, in dog.
Xenobiotica; the fate of foreign compounds in biological systems 1987;17(8):941-50.
1987: Bialer M; Wu W H; Look Z M; Silber B M; Yacobi A
Pharmacokinetics of cefixime after oral and intravenous doses in dogs: bioavailability assessment for a drug showing nonlinear serum protein binding.
Research communications in chemical pathology and pharmacology 1987;56(1):21-32.
1987: Bialer M; Batra V K; Morrison J A; Silber B M; Look Z M; Yacobi A
Dose-dependent pharmacokinetics of a new oral cephalosporin, cefixime, in the dog.
Pharmaceutical research 1987;4(1):33-7.
1986: Bialer M; Look Z M; Silber B M; Yacobi A
The relationship between drug input and mean residence time in the body.
Biopharmaceutics & drug disposition 1986;7(6):577-83.
1986: Yagen B; Sintov A; Bialer M
New, sensitive thin-layer chromatographic-high-performance liquid chromatographic method for detection of trichothecene mycotoxins.
Journal of chromatography 1986;356(1):195-201.
1986: Sintov A; Bialer M; Yagen B
Pharmacokinetics of T-2 toxin and its metabolite HT-2 toxin, after intravenous administration in dogs.
Drug metabolism and disposition: the biological fate of chemicals 1986;14(2):250-4.
1985: Yagen B; Bialer M; Sintov A
Gas chromatographic assay with pharmacokinetic applications for monitoring T-2 and HT-2 toxins in plasma.
Journal of chromatography 1985;343(1):67-75.

Sign-in to see more